{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T05:20:55Z","timestamp":1755926455592},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T00:00:00Z","timestamp":1590537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T00:00:00Z","timestamp":1590537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s00108-020-00811-2","type":"journal-article","created":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T12:02:52Z","timestamp":1590580972000},"page":"660-668","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Checkpoint-Inhibitoren bei Hodgkin-Lymphom"],"prefix":"10.1007","volume":"61","author":[{"given":"S.","family":"Sasse","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Momotow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Engert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,27]]},"reference":[{"key":"811_CR1","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell\u00a0SM, Lesokhin\u00a0AM, Borrello\u00a0I et al (2015) PD\u20111 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N\u00a0Engl J Med 372:311\u2013319","journal-title":"N Engl J Med"},{"key":"811_CR2","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","volume":"36","author":"P Armand","year":"2018","unstructured":"Armand\u00a0P, Engert\u00a0A, Younes\u00a0A et al (2018) Nivolumab for relapsed\/refractory classic Hodgkin Lymphoma after failure of Autologous Hematopoietic cell transplantation: extended follow-up of the Multicohort single-arm phase II checkmate 205 trial. J\u00a0Clin Oncol 36:1428\u20131439","journal-title":"J Clin Oncol"},{"key":"811_CR3","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","volume":"34","author":"P Armand","year":"2016","unstructured":"Armand\u00a0P, Shipp\u00a0MA, Ribrag\u00a0V et al (2016) Programmed death\u20111 blockade with Pembrolizumab in patients with classical Hodgkin Lymphoma after Brentuximab Vedotin failure. J\u00a0Clin Oncol 34:3733\u20133739","journal-title":"J Clin Oncol"},{"key":"811_CR4","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","volume":"390","author":"P Borchmann","year":"2018","unstructured":"Borchmann\u00a0P, Goergen\u00a0H, Kobe\u00a0C et al (2018) PET-guided treatment in patients with advanced-stage Hodgkin\u2019s lymphoma (HD18): Final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet 390:2790\u20132802","journal-title":"Lancet"},{"key":"811_CR5","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1080\/10428194.2016.1185789","volume":"57","author":"PJ Brockelmann","year":"2016","unstructured":"Brockelmann\u00a0PJ, Borchmann\u00a0P, Engert\u00a0A (2016) Current and future immunotherapeutic approaches in Hodgkin lymphoma. Leuk Lymphoma 57:2014\u20132024","journal-title":"Leuk Lymphoma"},{"key":"811_CR6","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020","author":"Br\u00f6ckelmann","year":"2020","unstructured":"Br\u00f6ckelmann et al (2020) Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma. The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2020.0750","journal-title":"JAMA Oncol"},{"key":"811_CR7","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","volume":"35","author":"R Chen","year":"2017","unstructured":"Chen\u00a0R, Zinzani\u00a0PL, Fanale\u00a0MA et\u00a0al (2017) Phase II study of the efficacy and safety of Pembrolizumab for relapsed\/refractory classic Hodgkin Lymphoma. J\u00a0Clin Oncol 35:2125\u20132132","journal-title":"J Clin Oncol"},{"key":"811_CR8","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1200\/JCO.19.00964","volume":"37","author":"M Fuchs","year":"2019","unstructured":"Fuchs\u00a0M, Goergen\u00a0H, Kobe\u00a0C et al (2019) Positron emission Tomography-guided treatment in early-stage favorable Hodgkin Lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group. J\u00a0Clin Oncol 37:2835\u20132845","journal-title":"J Clin Oncol"},{"key":"811_CR9","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","volume":"116","author":"MR Green","year":"2010","unstructured":"Green\u00a0MR, Monti\u00a0S, Rodig\u00a0SJ et al (2010) Integrative analysis reveals selective 9p24.1 amplification, increased PD\u20111 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B\u2011cell lymphoma. Blood 116:3268\u20133277","journal-title":"Blood"},{"key":"811_CR10","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","volume":"18","author":"MR Green","year":"2012","unstructured":"Green\u00a0MR, Rodig\u00a0S, Juszczynski\u00a0P et al (2012) Constitutive AP\u20111 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res 18:1611\u20131618","journal-title":"Clin Cancer Res"},{"key":"811_CR11","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","volume":"131","author":"AF Herrera","year":"2018","unstructured":"Herrera\u00a0AF, Moskowitz\u00a0AJ, Bartlett\u00a0NL et\u00a0al (2018) Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood 131:1183\u20131194","journal-title":"Blood"},{"key":"811_CR12","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.bbmt.2018.08.028","volume":"25","author":"A Ijaz","year":"2019","unstructured":"Ijaz\u00a0A, Khan\u00a0AY, Malik\u00a0SU et al (2019) Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after Allogeneic transplantation. Biol Blood Marrow Transplant 25:94\u201399","journal-title":"Biol Blood Marrow Transplant"},{"key":"811_CR13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/nrc2542","volume":"9","author":"R Kuppers","year":"2009","unstructured":"Kuppers\u00a0R (2009) The biology of Hodgkin\u2019s lymphoma. Nat Rev Cancer 9:15\u201327","journal-title":"Nat Rev Cancer"},{"key":"811_CR14","doi-asserted-by":"publisher","first-page":"e293","DOI":"10.1097\/HS9.0000000000000293","volume":"3","author":"J Momotow","year":"2019","unstructured":"Momotow\u00a0J, Goergen\u00a0H, Behringer\u00a0K et al (2019) Nivolumab in relapsed\/refractory classical Hodgkin Lymphoma\u2014extended follow-up of 30 patients treated within the checkmate 205 trial in a\u00a0single-center. HemaSphere 3:e293","journal-title":"HemaSphere"},{"key":"811_CR15","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","volume":"132","author":"CH Moskowitz","year":"2018","unstructured":"Moskowitz\u00a0CH, Walewski\u00a0J, Nademanee\u00a0A et al (2018) Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood 132:2639\u20132642","journal-title":"Blood"},{"key":"811_CR16","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1182\/blood-2019-122535","volume":"134","author":"SS Patel","year":"2019","unstructured":"Patel\u00a0SS, Weirather\u00a0JL, Lipschitz\u00a0M et al (2019) The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative. Blood 134:2059\u20132069","journal-title":"Blood"},{"key":"811_CR17","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1200\/JCO.19.00315","volume":"37","author":"R Ramchandren","year":"2019","unstructured":"Ramchandren\u00a0R, Domingo-Domenech\u00a0E, Rueda\u00a0A et al (2019) Nivolumab for newly diagnosed advanced-stage classic Hodgkin Lymphoma: safety and efficacy in the phase II checkmate 205 study. J\u00a0Clin Oncol 37:1997\u20132007","journal-title":"J Clin Oncol"},{"key":"811_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25154","author":"C Rossi","year":"2018","unstructured":"Rossi C, Gilhodes J, Maerevoet M et al (2018) Efficacy of chemotherapy or chemo-anti-PD\u20111 combination after failed anti-PD\u20111 therapy for relapsed and refractory Hodgkin lymphoma: a series from Lysa centers. Am J Hematol. https:\/\/doi.org\/10.1002\/ajh.25154","journal-title":"Am J Hematol"},{"key":"811_CR19","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1200\/JCO.2016.70.9410","volume":"35","author":"S Sasse","year":"2017","unstructured":"Sasse\u00a0S, Brockelmann\u00a0PJ, Goergen\u00a0H et al (2017) Long-term follow-up of contemporary treatment in early-stage Hodgkin Lymphoma: updated analyses of the German Hodgkin study group HD7, HD8, HD10, and HD11 trials. J\u00a0Clin Oncol 35:1999\u20132007","journal-title":"J Clin Oncol"},{"key":"811_CR20","doi-asserted-by":"publisher","first-page":"474","DOI":"10.3324\/haematol.2015.136408","volume":"101","author":"D Sibon","year":"2016","unstructured":"Sibon\u00a0D, Morschhauser\u00a0F, Resche-Rigon\u00a0M et al (2016) Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA\/SFGM-TC study group. Haematologica 101:474\u2013481","journal-title":"Haematologica"},{"key":"811_CR21","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3324\/haematol.2011.045757","volume":"97","author":"A Sureda","year":"2012","unstructured":"Sureda\u00a0A, Canals\u00a0C, Arranz\u00a0R et al (2012) Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin\u2019s lymphoma. Results of the HDR-ALLO study\u2014a\u00a0prospective clinical trial by the Grupo Espanol de Linfomas\/Trasplante de Medula Osea (GEL\/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 97:310\u2013317","journal-title":"Haematologica"},{"key":"811_CR22","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1182\/blood-2017-07-796342","volume":"131","author":"F Vari","year":"2018","unstructured":"Vari\u00a0F, Arpon\u00a0D, Keane\u00a0C et al (2018) Immune evasion via PD-1\/PD-L1 on NK cells and monocyte\/macrophages is more prominent in Hodgkin lymphoma than DLBCL. Blood 131:1809\u20131819","journal-title":"Blood"},{"key":"811_CR23","doi-asserted-by":"publisher","first-page":"e462","DOI":"10.1016\/S2352-3026(18)30140-6","volume":"5","author":"B Von Tresckow","year":"2018","unstructured":"Von Tresckow\u00a0B, Kreissl\u00a0S, Goergen\u00a0H et al (2018) Intensive treatment strategies in advanced-stage Hodgkin\u2019s lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials. Lancet Haematol 5:e462\u2013e473","journal-title":"Lancet Haematol"},{"key":"811_CR24","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1200\/JCO.2011.38.5807","volume":"30","author":"B Von Tresckow","year":"2012","unstructured":"Von Tresckow\u00a0B, Plutschow\u00a0A, Fuchs\u00a0M et al (2012) Dose-intensification in early unfavorable Hodgkin\u2019s lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J\u00a0Clin Oncol 30:907\u2013913","journal-title":"J Clin Oncol"},{"key":"811_CR25","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1158\/2326-6066.CIR-17-0325","volume":"5","author":"F Wein","year":"2017","unstructured":"Wein\u00a0F, Weniger\u00a0MA, Hoing\u00a0B et\u00a0al (2017) Complex immune evasion strategies in classical Hodgkin Lymphoma. Cancer Immunol Res 5:1122\u20131132","journal-title":"Cancer Immunol Res"},{"key":"811_CR26","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","volume":"17","author":"A Younes","year":"2016","unstructured":"Younes\u00a0A, Santoro\u00a0A, Shipp\u00a0M et al (2016) Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a\u00a0multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 17:1283\u20131294","journal-title":"Lancet Oncol"},{"key":"811_CR27","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1182\/blood-2019-127280","volume":"134","author":"PL Zinzani","year":"2019","unstructured":"Zinzani\u00a0PL, Lee\u00a0HJ, Armand\u00a0P et al (2019) Three-year follow-up of keynote-087: Pembrolizumab Monotherapy in relapsed\/refractory classic Hodgkin Lymphoma. Blood 134:240","journal-title":"Blood"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-020-00811-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-020-00811-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-020-00811-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T23:13:35Z","timestamp":1622070815000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-020-00811-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,27]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["811"],"URL":"https:\/\/doi.org\/10.1007\/s00108-020-00811-2","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,27]]},"assertion":[{"value":"27 May 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S.\u00a0Sasse und J.\u00a0Momotow geben an, dass kein Interessenkonflikt besteht. A.\u00a0Engert: Beratungs- und Gutachtert\u00e4tigkeit: Takeda\/Millennium, BMS, MSD, Affimed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}